23 results
SC 14D9/A
EX-99
CBAY
Cymabay Therapeutics Inc
7 Mar 24
Tender offer solicitation (amended)
4:35pm
seladelpar to the next step. With their leadership we can get seladelpar into the hands of more providers and help people living with PBC live healthier … lives around the world.
Why Gilead?
Gilead has a long history of leadership in liver diseases and launching new therapies. It has strong relationships
SC 14D9
CBAY
Cymabay Therapeutics Inc
23 Feb 24
Tender offer solicitation
6:25am
a standstill provision.
On January 6, 2024, representatives of the Company met with senior leadership of Company C to discuss the seladelpar program
SC TO-T
EX-99
CBAY
Cymabay Therapeutics Inc
23 Feb 24
Third party tender offer statement
6:09am
USA), where she was a member of the faculty for more than 30 years and served as the Norman Davidson Leadership Chair of the division from 2009 … more than 20 years of increasing company leadership and commitment to transforming care delivery for patients with
Schedule A-4
Name, Country
8-K
CBAY
Cymabay Therapeutics Inc
21 Dec 23
Other Events
4:01pm
Offer Letter dated March 24, 2021. Ben Kozub, VP Liver Franchise Lead, will assume leadership of the commercial organization effective immediately. Mr
PRER14A
gymhnvj gw6
5 May 20
Preliminary revised proxy
4:25pm
PRRN14A
6aa c7fawvgxu
1 May 20
Revised preliminary proxy statement filed by non-management
2:50pm
PREC14A
m39tn iocsk9
27 Apr 20
Preliminary proxy with contested solicitation
4:42pm
PREC14A
p2c oh1wlvlrqub
24 Apr 20
Preliminary proxy with contested solicitation
4:50pm
424B4
iqfrw xvlv2lzwew359
22 Jul 14
Prospectus supplement with pricing info
12:00am
8-K
EX-99.1
ua6d q86n0
13 Jan 14
Regulation FD Disclosure
12:00am
424B3
jlhus4o a2bd7
6 Jan 14
Prospectus supplement
12:00am
S-1
eyaruhsd
29 Nov 13
IPO registration
12:00am
10-12G/A
fqtwp6tx2tsvgswwe
22 Nov 13
Registration of securities (amended)
12:00am
10-12G/A
l9b5d u9zkbk85
8 Nov 13
Registration of securities (amended)
12:00am